Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.59 |
| ▸ | JAK1 | P23458 | 4/20 | 0.56 |
| ▸ | JAK2 | O60674 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PLCG1 | P19174 | 4/20 | 0.53 |
| ▸ | BTK | Q06187 | 4/20 | 0.52 |
| ▸ | ITK | Q08881 | 2/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17939611 | 0.83 | PLCG1 (0.77) | PLCG1BTKITK | |
| SCHEMBL1444775 | 0.82 | FYN (0.56) | JAK3 | |
| SCHEMBL28144707 | 0.76 | CYP17A1 (0.59) | — | |
| SCHEMBL24150634 | 0.75 | JAK3 (0.68) | JAK3JAK1JAK2EGFRPLCG1 | |
| SCHEMBL30190947 | 0.75 | JAK3 (0.68) | JAK3JAK1JAK2EGFRPLCG1 | |
| SCHEMBL30190528 | 0.75 | JAK3 (0.58) | JAK3JAK1PLCG1BTKITK | |
| SCHEMBL24151660 | 0.75 | JAK3 (0.58) | JAK3JAK1PLCG1BTKITK | |
| SCHEMBL30191150 | 0.75 | JAK3 (0.74) | JAK3JAK1JAK2EGFRPLCG1 | |
| SCHEMBL24151517 | 0.75 | JAK3 (0.74) | JAK3JAK1JAK2EGFRPLCG1 | |
| SCHEMBL24150540 | 0.75 | JAK3 (0.60) | JAK3JAK1EGFRPLCG1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-04-29 | — | — | US | disclosed |
| US-20230122912-A1 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-04-20 | — | — | US | disclosed |
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | UNIVERSISITY OF UTAH RESEARCH FOUNDATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210171502-A1 | METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS | UNITED STATES GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
| EP-3680238-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | University of Utah Research Foundation (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-2903971-B1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIV UTAH RES FOUND (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2018-05-17 | — | — | US | disclosed |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2018-05-17 | — | — | US | disclosed |
| EP-2694486-B1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIV UTAH RES FOUND (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9828376-B2 | Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2014055928-A2 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014055934-A2 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014055934-A2 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014055928-A2 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-04-10 | — | — | WO | disclosed |
| EP-2694486-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694486-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130059847-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2013-03-07 | — | — | US | disclosed |
| US-20130059847-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2013-03-07 | — | — | US | disclosed |
| WO-2012135801-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135801-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171502-A1 | METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS | BCL9, BCL9L, BCL3 | JAK3 3056/4885JAK1 3373/4885JAK2 1442/4885 |
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | JAK3 3203/4885JAK1 3236/4885JAK2 1436/4885 |
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | JAK3 3051/4885JAK1 3044/4885JAK2 1170/4885 |
| US-20130059847-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | JAK3 58/4885JAK1 42/4885JAK2 20/4885 |
| US-20230122912-A1 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | BCL9, BCL9L, BCL3 | JAK3 3373/4885JAK1 3264/4885JAK2 1338/4885 |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | JAK3 58/4885JAK1 42/4885JAK2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.